# Pan-tumor MRD Study

> **NCT06605404** · — · RECRUITING · sponsor: **Paradigm Health** · enrollment: 1350 (estimated)

## Conditions studied

- Muscle Invasive Bladder Urothelial Carcinoma
- Esophageal Cancer
- Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
- Melanoma (Skin Cancer)
- NSCLC (Non-small Cell Lung Cancer)
- Pancreatic (Exocrine Only)
- Mix of Solid Tumors (MOST)

## Interventions

- **DIAGNOSTIC_TEST:** blood and tissue samples
- **OTHER:** blood and tissue samples

## Key facts

- **NCT ID:** NCT06605404
- **Lead sponsor:** Paradigm Health
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-08
- **Primary completion:** 2031-12
- **Final completion:** 2032-04
- **Target enrollment:** 1350 (ESTIMATED)
- **Last updated:** 2025-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06605404

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06605404, "Pan-tumor MRD Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06605404. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*